Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CCKAR | P32238 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1156992 | 0.99 | ALDH3A1 (0.44) | ALDH3A1HTR6KMT2AGAACCKAR | |
| SCHEMBL1156132 | 0.88 | ELAVL1 (0.42) | ALDH3A1HTR6KMT2AGAASMN1; SMN2 | |
| SCHEMBL1580382 | 0.88 | TUBB4A (0.38) | ALDH3A1PTGDR2 | |
| Hydrochloric Acid SCHEMBL1157261 | 0.87 | TUBB4A (0.37) | ALDH3A1PTGDR2 | |
| SCHEMBL1580766 | 0.86 | HTR6 (0.43) | HTR6 | |
| SCHEMBL1580383 | 0.86 | LMNA (0.43) | ALDH3A1HTR6KMT2AGAAMEN1 | |
| Hydrochloric Acid SCHEMBL1156349 | 0.85 | HTR6 (0.42) | HTR6 | |
| Hydrochloric Acid SCHEMBL1156771 | 0.85 | LMNA (0.42) | ALDH3A1HTR6KMT2AGAAMEN1 | |
| SCHEMBL1580822 | 0.84 | ALOX5 (0.41) | HTR6 | |
| SCHEMBL1156619 | 0.84 | L3MBTL1 (0.47) | ALDH3A1HTR6KMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186411-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | US | disclosed |
| EP-2564833-A1 | Photostabilized pharmaceutical composition | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | ALDH3A1 2636/4885HTR6 1727/4885KMT2A 1862/4885 |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | ALDH3A1 2636/4885HTR6 1727/4885KMT2A 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.